Gut Microbiota Composition and Plasma Metabolomic Profile Are Associated with Amyloid Pathology and Cognitive Performance in Patients with Mild Cognitive Impairment
Nutrients · 07.07.2026 · 18 (13) · 2200
DOI: 10.3390/nu18132200 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, online erschienen am 07.07.2026. Verfasst von Marina Mora-Ortiz und 14 weiteren Autor:innen. Beteiligte Einrichtung: Lipids and Atherosclerosis Unit, Department of Internal Medicine, Reina Sofia University Hospital, 14004 Cordoba, Spain. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Gastrointestinal Microbiome, Amyloid beta-Peptides, Cognition. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Regional Government of Andalusia, MEMOIR.
Abstract (Originalsprache)
Background/Objectives: The gut–brain axis and systemic metabolic dysregulation are increasingly implicated in Alzheimer’s disease (AD) pathogenesis. This study aimed to characterize gut microbiota and plasma metabolomic profiles associated with amyloid pathology and cognitive impairment in patients with mild cognitive impairment (MCI).
Methods
A cross-sectional multi-omics baseline analysis was performed in 47 MCI patients enrolled in a randomized, double-blind, crossover dietary intervention trial (NCT05029765). Gut microbiota composition was assessed by 16S rRNA sequencing (n = 47), and plasma metabolomics by untargeted LC-MS/MS (n = 45 after exclusion of two PCA-defined metabolomic outliers). Patients were stratified according to plasma amyloid-beta 42/40 ratio (BA42/40) and ADAScog11 score, representing complementary biomarkers of amyloid burden and cognitive impairment, respectively.
Results
Higher amyloid burden and worse cognitive performance were associated with significant gut microbiota alterations, including increased alpha diversity and distinct beta diversity profiles. Differential abundance analyses consistently showed enrichment of Bacteroides-associated taxa and Akkermansia, alongside depletion of short-chain fatty acid-producing genera such as Faecalibacterium, Blautia, and Phascolarctobacterium. Plasma metabolomics identified a coherent signature associated with elevated BA42/40, characterized by accumulation of secondary bile acid sulfates and depletion of sphingolipids, neuroactive steroids, and anti-inflammatory lipid mediators, including pregnenolone sulfate, resolvin E1, and anandamide. A valid OPLS-DA discriminant model was obtained for BA42/40, whereas no predictive model was achieved for ADAScog11. Critically, this dissociation, characterized by significant microbiota differences but no metabolomic separation for ADAScog11, is itself an informative finding, suggesting that gut microbiota dysbiosis and plasma metabolomic alterations are not equally coupled to both dimensions of MCI pathophysiology.
Conclusions
MCI patients with greater amyloid pathology and cognitive impairment exhibited gut microbiota dysbiosis. However, metabolic associations were observed only for BA42/40, but not for ADAScog11. These findings provide a mechanistic framework for evaluating the impact of Mediterranean diet and probiotic interventions in the longitudinal phase of the trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lipids and Atherosclerosis Unit, Department of Internal Medicine, Reina Sofia University Hospital, 14004 Cordoba, Spain.
- Department of Medical and Surgical Sciences, Universidad de Cordoba, 14004 Cordoba, Spain.
- GC-09, Nutrigenomics and Metabolic Syndrome, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.
- Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), University of Cordoba, 14004 Cordoba, Spain.
- Department of Analytical Chemistry and Nanochemistry University Institute, Universidad de Cordoba, 14071 Cordoba, Spain.
- CIBER de Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III, 28029 Madrid, Spain.
ORCID-Profile: Marina Mora-Ortiz, Magdalena P Cardelo, Carlos A Ledesma-Escobar, Feliciano Priego-Capote, Cristina Conde-Gavilán, Eduardo Agüera-Morales, Antonio Camargo
Förderung
- Instituto de Salud Carlos III
- Regional Government of Andalusia
- MEMOIR
- European Union’s Horizon 2020 research and innovation programme
- Institute of Health Carlos III
- Andalusian Regional Government
Zitieren
APA
Mora-Ortiz, M., Cardelo, M. P., Porras-Pérez, E., Serrán-Jiménez, A., Ledesma-Escobar, C. A., Priego-Capote, F., Conde-Gavilán, C., Agüera-Morales, E., Pineda Reyes, R., Malagon, M. M., Yubero-Serrano, E. M., Camargo, A., Katsiki, N., López-Miranda, J., & Perez-Martinez, P. (2026). Gut Microbiota Composition and Plasma Metabolomic Profile Are Associated with Amyloid Pathology and Cognitive Performance in Patients with Mild Cognitive Impairment. Nutrients, 18(13), 2200. https://doi.org/10.3390/nu18132200
Vancouver
Mora-Ortiz M, Cardelo MP, Porras-Pérez E, Serrán-Jiménez A, Ledesma-Escobar CA, Priego-Capote F, et al. Gut Microbiota Composition and Plasma Metabolomic Profile Are Associated with Amyloid Pathology and Cognitive Performance in Patients with Mild Cognitive Impairment. Nutrients. 2026;18(13):2200. doi:10.3390/nu18132200
BibTeX
@article{MoraOrtiz2026,
author = {Mora-Ortiz, Marina and Cardelo, Magdalena P and Porras-Pérez, Esther and Serrán-Jiménez, Alejandro and Ledesma-Escobar, Carlos A and Priego-Capote, Feliciano and Conde-Gavilán, Cristina and Agüera-Morales, Eduardo and Pineda Reyes, Rafael and Malagon, Maria M and Yubero-Serrano, Elena M and Camargo, Antonio and Katsiki, Niki and López-Miranda, José and Perez-Martinez, Pablo},
title = {Gut Microbiota Composition and Plasma Metabolomic Profile Are Associated with Amyloid Pathology and Cognitive Performance in Patients with Mild Cognitive Impairment},
journal = {Nutrients},
year = {2026},
volume = {18},
number = {13},
pages = {2200},
doi = {10.3390/nu18132200}
}
EUVIMED